Goldman Sachs
ALBO

Goldman Sachs’s Albireo Pharma Inc ALBO Stock Holding History

Goldman Sachs’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,837
Closed -$174K – 6836
2013
Q3 		$174K Buy
1,837
+1,737
+1,737% +$226K ﹤0.01% 5953
2013
Q2 		$13K Buy
+100
New +$10.4K ﹤0.01% 6233

Other funds holding ALBO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's ALBO Position: Q1 2023 in Review

Goldman Sachs sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 12,706 shares — an estimated $275K sold.

Goldman Sachs first reported a position in ALBO in Q2 2013 and held it in 30 quarters. The position peaked at $8.18M in Q4 2020. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.

  • Goldman Sachs reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
  • Goldman Sachs sold 12,706 Albireo Pharma Inc shares in Q1 2023, an estimated $275K.
  • Goldman Sachs first reported a position in Albireo Pharma Inc in Q2 2013 and held it in 30 quarters.
  • Goldman Sachs's Albireo Pharma Inc position peaked at $8.18M in Q4 2020.
  • 3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.